Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions
Open Access
- 1 October 2022
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200118
Abstract
There is not much information on hepatocellular carcinoma (HCC) in India. Here, we review the existing data, available treatment choices, and future directions in HCC management. An extensive search was conducted through PubMed and MEDLINE for studies published between January 2000 and June 2022 on the epidemiology of HCC in India using the following key words: atezolizumab, BCLC staging, hepatocellular carcinoma, immune checkpoint inhibitors, immunotherapy, and programmed cell death ligand-1, with the filters humans and English language. The most frequent risk factors for the development of HCC in India include nonalcoholic fatty liver disease, hepatitis B virus and hepatitis C virus infection, liver cirrhosis, and alcohol intake. On the basis of new findings, the Barcelona Clinic Liver Cancer (BCLC) Staging Criteria need to be revised. As most cases in India are discovered at a later stage, curative treatments such as surgical resection, ablation, or liver transplantation may not be an option. Clinical trials are underway for a number of immune checkpoint drugs that target cytotoxic T-cell lymphocyte-4 and programmed cell death-1/programmed cell death-ligand 1. In India, phase III trials of atezolizumab in combination with other drugs are underway for the treatment of various malignancies. Renin angiotensin system inhibitors, antivirals, primary hepatocyte transplantation, and bioartificial liver devices are among the future options for the management of HCC. In developing countries like India, HCC is often diagnosed at an advanced stage because of a delay in routine testing or screening. Therefore, developing effective treatment regimens for such stages is critical. Immunotherapy is a promising treatment option that has the potential to increase overall response and survival rate.Keywords
This publication has 69 references indexed in Scilit:
- Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECISTSeminars in Liver Disease, 2014
- Epidemiology of Hepatocellular Carcinoma in IndiaJournal of Clinical and Experimental Hepatology, 2014
- Risk Factors for Hepatocellular Carcinoma in IndiaJournal of Clinical and Experimental Hepatology, 2014
- Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapyHepatology, 2013
- Cancer mortality in India: a nationally representative surveyThe Lancet, 2012
- Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in IndiaIndian Journal of Radiology and Imaging, 2011
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatology International, 2010
- Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 casesQJM: An International Journal of Medicine, 2008
- Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase testJournal of Medical Microbiology, 2007
- Injection practices in Southern part of IndiaPublic Health, 2003